<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Imaging Biol</journal-id><journal-id journal-id-type="iso-abbrev">Mol Imaging Biol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Molecular Imaging and Biology</journal-title></journal-title-group><issn pub-type="ppub">1536-1632</issn><issn pub-type="epub">1860-2002</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11805767</article-id><article-id pub-id-type="pmcid-ver">PMC11805767.1</article-id><article-id pub-id-type="pmcaid">11805767</article-id><article-id pub-id-type="pmcaiid">11805767</article-id><article-id pub-id-type="pmid">39810067</article-id><article-id pub-id-type="doi">10.1007/s11307-024-01975-1</article-id><article-id pub-id-type="publisher-id">1975</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Oral Administration of [<sup>18</sup>F]MC225 for Quantification of P-glycoprotein Function: A Feasibility Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Salvi de Souza</surname><given-names initials="G">Giordana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Furini</surname><given-names initials="CRG">Cristiane R. G.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sijbesma</surname><given-names initials="JWA">J&#252;rgen W. A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kominia</surname><given-names initials="M">Maria</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doorduin</surname><given-names initials="J">Janine</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Giacobbo</surname><given-names initials="BL">Bruno Lima</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lammertsma</surname><given-names initials="AA">Adriaan A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsoumpas</surname><given-names initials="C">Charalampos</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8599-8129</contrib-id><name name-style="western"><surname>Luurtsema</surname><given-names initials="G">Gert</given-names></name><address><email>g.luurtsema@umcg.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03cv38k47</institution-id><institution-id institution-id-type="GRID">grid.4494.d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9558 4598</institution-id><institution>Department of Nuclear Medicine and Molecular Imaging, </institution><institution>University Medical Center Groningen, University of Groningen, </institution></institution-wrap>Groningen, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/025vmq686</institution-id><institution-id institution-id-type="GRID">grid.412519.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2166 9094</institution-id><institution>School of Medicine, </institution><institution>PUCRS, </institution></institution-wrap>Porto Alegre, Brazil </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/025vmq686</institution-id><institution-id institution-id-type="GRID">grid.412519.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2166 9094</institution-id><institution>Laboratory of Cognition and Memory Neurobiology, </institution><institution>Brain Institute, PUCRS, </institution></institution-wrap>Porto Alegre, Brazil </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>27</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">481680</issue-id><fpage>89</fpage><lpage>98</lpage><history><date date-type="received"><day>25</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>18</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-11 21:25:28.443"><day>11</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="11307_2024_Article_1975.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">This preclinical study explored the feasibility of assessing P-glycoprotein (P-gp) function in both brain and gastrointestinal (GI) tract of rats using positron emission tomography (PET) following oral administration of [<sup>18</sup>F]MC225. Different oral administration protocols were evaluated, and radioactivity uptake was compared with uptake following intravenous administration.</p></sec><sec><title>Procedures</title><p id="Par2">Twelve male Wistar rats were divided into four groups and subjected to intravenous or oral [<sup>18</sup>F]MC225 administration protocols: G<sub>1</sub> (intravenous route), G<sub>2</sub> (oral administration without fasting), G<sub>3</sub> (oral administration with fasting), and G<sub>4</sub> (oral administration with fasting following administration of the P-gp inhibitor tariquidar). Dynamic brain imaging, late abdominal imaging, <italic toggle="yes">ex vivo</italic> biodistribution, and metabolite analysis were conducted to assess tracer distribution.</p></sec><sec><title>Results</title><p id="Par3">In the brain, oral administration yielded lower values compared with intravenous administration, resulting in a reduction in the tissue-to-plasma ratio by approximately 51% for the cortex and 45% for the midbrain and cerebellum. Fasting improved radioactivity uptake, aiding brain visualization. Unexpectedly, administration of the P-gp inhibitor tariquidar did not increase brain concentration, suggesting a signal that was dominated by non-specific uptake, possibly due to instability of [<sup>18</sup>F]MC225 in the GI tract. Metabolite analysis in G<sub>4</sub> indicated a significant presence of polar metabolites.</p></sec><sec><title>Conclusions</title><p id="Par4">Oral administration of [<sup>18</sup>F]MC225 faces challenges and, at this stage, cannot be used to quantify P-gp function. Further research to assess tracer stability and metabolism in the stomach and intestine will be essential for advancing the feasibility of oral tracer administration.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s11307-024-01975-1.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Biodistribution</kwd><kwd>Gastrointestinal tract</kwd><kwd>P-glycoprotein</kwd><kwd>Positron emission tomography</kwd></kwd-group><funding-group><award-group><funding-source><institution>Abel Tasman Talent Program (ATTP) of the Graduate School of Medical Sciences of the University of Groningen, the Netherlands.</institution></funding-source><award-id>Abel Tasman Talent Program (ATTP) of the Graduate School of Medical Sciences of the University of Groningen, the Netherlands.</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; World Molecular Imaging Society 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par5">P-glycoprotein (P-gp) is a member of the adenosine triphosphate (ATP)-binding-cassette (ABC) transporter family, which acts as a membrane efflux pump [<xref ref-type="bibr" rid="CR1">1</xref>]. It is primarily expressed in the liver, kidneys, gastrointestinal (GI) tract, pancreas, and the blood-brain barrier (BBB) [<xref ref-type="bibr" rid="CR2">2</xref>]. P-gp expression in these sites impacts absorption, distribution, metabolism, and elimination of various substrates, including antibiotics, immunosuppressive agents, anticancer drugs, and more [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. In the GI tract, P-gp-mediated efflux across the apical membrane of enterocytes affects the rate and concentration of drugs diffusing across the basolateral membrane and entering general circulation from the intestine [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Meanwhile, in the brain, P-gp acts as a gatekeeper, dynamically regulating the infiltration of substrates into the central nervous system (CNS), posing a critical challenge to the effectiveness of pharmacotherapies for neurological conditions [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par6">The normal procedure for administering PET tracers is via intravenous (i.v.) injection. Although this procedure is the gold standard in both clinical practice and research studies, it limits the understanding of transport mechanisms from the intestinal epithelium into the GI tract lumen. Hence, oral administration of tracers has been proposed to investigate transport across various biological barriers, providing additional insights into the effects of transporters on drug tissue kinetics and delivery [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. However, challenges such as limited intestinal absorption, potential delays in organ uptake, and effects of food and acidity on tracer absorption must be addressed to ensure the reliability and reproducibility of tissue quantification obtained after oral administration [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par7">One method to quantify P-gp function involves the use of a radiolabeled P-gp substrate. It has been demonstrated that [<sup>18</sup>F]MC225, a specific and selective tracer of P-gp function, enables visualization of distribution and quantification of transport throughout the body using positron emission tomography (PET) [<xref ref-type="bibr" rid="CR12">12</xref>]. While current clinical studies shed light on P-gp distribution in the brain [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>], understanding how this distribution changes across the entire body and its relation to the GI tract poses an ongoing research challenge. Moreover, P-gp plays a dynamic role in determining the bioavailability of orally administered drugs [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, to understand why many drugs fail to reach the brain, it is crucial to determine whether the primary factor is their absorption through the intestinal epithelium or permeability of the BBB [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par8">The aim of this preclinical pilot study was to assess whether oral administration of [<sup>18</sup>F]MC225 is a feasible option for PET imaging of both brain and GI tract. To this end, various oral administration protocols were evaluated, comparing uptake in brain and GI tract with that following intravenous administration.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>[18F]MC225 Radiosynthesis</title><p id="Par9">[<sup>18</sup>F]MC225 was manufactured at the Department of Nuclear Medicine and Molecular Imaging of the University Medical Center Groningen (EU-GMP production license: 108964&#160;F). The molar activity was higher than 25,000 GBq/mmol and the radiochemical purity was higher than 98% in all cases. Production and quality control procedures of [<sup>18</sup>F]MC225 were performed as previously described [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p></sec></sec><sec id="Sec4"><title>Animals</title><p id="Par10">This study was performed in accordance with the Animal Welfare Act of the European Communities Council Directive. The protocol was approved by the National Committee on Animal Experiments of the Netherlands and the Institutional Animal Care and Use Committee of the University of Groningen (CCD license: AVD105020198648, IvD protocol: 198648-01-005). All applicable institutional and/or national guidelines for the care and use of animals were followed.</p><p id="Par11">Twelve adults male Wistar rats (Crl: WI(WU)) were obtained from Charles River Laboratories (Sulzfeld, Germany). Only male rats were selected to minimize the impact of the estrogen cycle on P-gp function at the BBB, as sex differences in the distribution of P-gp have been reported in animals [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par12">Animals were acclimatized at the Central Animal Facility of the University Medical Center Groningen for at least 7 days before starting experiments. They were group housed in a temperature and humidity-controlled room with unlimited access to food and water.</p></sec><sec id="Sec5"><title>Experimental Design</title><p id="Par13">In this pilot study, four groups of animals were used. The first group was the control group with a standard intravenous tracer injection. The other three groups received an oral administration of [<sup>18</sup>F]MC225, each group with a different protocol.</p><sec id="Sec6"><title>Control Group: Intravenous Administration Group</title><p id="Par14">The intravenous group, G<sub>1</sub> (<italic toggle="yes">n</italic>&#8201;=&#8201;3, body weight of 309&#8201;&#177;&#8201;8&#160;g), was first anaesthetized with a mixture of 0.02 mL/g of ketamine and dexmedetomidine. This anesthetic combination was used because it has been shown not to alter intestinal motility compared with isoflurane, propofol, and pentobarbital [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. The animals were intravenously injected with 28.0&#8201;&#177;&#8201;8.0 MBq in a tail vein, while positioned in the PET scanner, using an infusion pump at a rate of 1 mL/min with a total administered volume of 1 mL.</p></sec><sec id="Sec7"><title>Oral Administration Groups</title><p id="Par15">The oral administration methodology was based on a previous scoping review [<xref ref-type="bibr" rid="CR8">8</xref>], which guided the selection of acquisition protocols to optimize tracer administration. Previous studies indicated that oral routes typically require approximately 40&#8211;70% of the radioactivity used for i.v. injections to reduce scattering and prevent high tracer concentrations in localized areas (e.g., stomach) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. The gavage technique was selected for oral administration. This method delivers the tracer near the gastro-esophageal sphincter, allowing gravity to facilitate its entry into the stomach [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par16">Tracer production for oral administration followed the same method as for i.v. administration [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. [<sup>18</sup>F]MC225, diluted in 1 mL saline, was administrated using disposable needles. For G<sub>2</sub>, the gavage needle used was Cadence Science 9918 (18G), from Fisher Scientific (Landsmeer, the Netherlands). However, close inspection indicated that changing the needle type could facilitate tracer administration more effectively, prompting a switch of needles. For one animal in G<sub>3</sub> and the entire G<sub>4</sub>, the needles were substituted with FTP-15&#8211;78-SAM from Instech Laboratories (Plymouth, USA). Animals were awake during administration to monitor whether there were any complications. Following oral administration, 0.5 mL of saline was administered to flush the esophagus, ensuring that the tracer reached the stomach.</p><p id="Par17">In the second group, G<sub>2</sub> (<italic toggle="yes">n</italic>&#8201;=&#8201;3 body weight 324&#8201;&#177;&#8201;4&#160;g), the tracer was administered orally via gavage with an activity of 8.8&#8201;&#177;&#8201;1.7 MBq. Subsequently, animals were anesthetized using the same combination of anesthetics as for G<sub>1</sub>.</p><p id="Par18">The third group, G<sub>3</sub> (<italic toggle="yes">n</italic>&#8201;=&#8201;3, body weight 302&#8201;&#177;&#8201;11&#160;g), received the tracer orally via gavage as well, but with a higher activity of 17.0&#8201;&#177;&#8201;0.7 MBq. In addition, these animals underwent a fasting period of 12&#8211;14&#160;h prior to the scan. The protocol modifications between G<sub>3</sub> and G<sub>2</sub> were introduced to assess whether higher radioactivity uptake, better image quality and more accurate quantification could be obtained.</p><p id="Par19">To estimate whether oral administration could also detect any changes in P-gp function, the P-gp inhibitor tariquidar was administered in the fourth group. Previous studies using [<sup>18</sup>F]MC225 have indicated that doses higher than 3&#160;mg/kg of tariquidar could significantly impact brain P-gp uptake in rats [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. To avoid the need for anesthesia, which would be needed for i.v. administration, tariquidar was administered intraperitoneally (i.p.). Previous studies have shown that the effects of tariquidar in rats remain constant and comparable to those after i.v. injection [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par20">Tariquidar was prepared in a vehicle solution of 5% dimethyl sulfoxide (DMSO), 10% TWEEN 20, 25% polyethylene glycol 400 (PEG400), and 65% H<sub>2</sub>O, following the same protocol as for i.v. administration [<xref ref-type="bibr" rid="CR15">15</xref>]. A dose of 10&#160;mg/kg, selected as an intermediate value based on previous studies, was administered [<xref ref-type="bibr" rid="CR15">15</xref>]. Group G<sub>4</sub> (<italic toggle="yes">n</italic>&#8201;=&#8201;3, body weight 286&#8201;&#177;&#8201;30&#160;g) received a dose of 10.1&#8201;&#177;&#8201;1.6&#160;mg/kg of tariquidar, with an average volume of 0.86&#8201;&#177;&#8201;0.21 mL (Bio-Techne Ltd., Abingdon, UK), 1&#160;h before tracer administration. This timing was chosen to ensure that tariquidar&#8217;s peak concentration, which occurs 2&#160;h after i.p. injection, coincided with tracer acquisition [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par21">The tracer, with an activity of 16.6&#8201;&#177;&#8201;3.2 MBq, was administered via oral gavage following a 12&#8211;14&#160;h fasting period prior to the scan. Table&#160;<xref rid="Tab1" ref-type="table">1</xref> summarizes the groups, body weights, administered activities and routes, and time between tracer administration and start of scan.</p><p id="Par22">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Description of experimental groups and administration protocols. Results expressed in mean&#8201;&#177;&#8201;SD, and [range]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Group</th><th align="left" colspan="1" rowspan="1">Body weight (g)</th><th align="left" colspan="1" rowspan="1">Age (weeks)</th><th align="left" colspan="1" rowspan="1">Activity (MBq)</th><th align="left" colspan="1" rowspan="1">Activity (MBq/g)</th><th align="left" colspan="1" rowspan="1">Administration Route</th><th align="left" colspan="1" rowspan="1">Delay (min)<sup>1</sup></th><th align="left" colspan="1" rowspan="1">Additional information</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">G<sub>1</sub></td><td align="left" colspan="1" rowspan="1"><p>309.1&#8201;&#177;&#8201;10.1</p><p>[18.7]</p></td><td align="left" colspan="1" rowspan="1"><p>9.3&#8201;&#177;&#8201;0.5</p><p>[1]</p></td><td align="left" colspan="1" rowspan="1"><p>28.0&#8201;&#177;&#8201;9.8</p><p>[17.9]</p></td><td align="left" colspan="1" rowspan="1"><p>31.0&#8201;&#177;&#8201;9.4</p><p>[18.0]</p></td><td align="left" colspan="1" rowspan="1">Intravenous</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">G<sub>2</sub></td><td align="left" colspan="1" rowspan="1"><p>323.6&#8201;&#177;&#8201;4.9</p><p>[9.6]</p></td><td align="left" colspan="1" rowspan="1"><p>10&#8201;&#177;&#8201;0.0</p><p>[0]</p></td><td align="left" colspan="1" rowspan="1"><p>8.8&#8201;&#177;&#8201;2.1</p><p>[3.9]</p></td><td align="left" colspan="1" rowspan="1"><p>15.6&#8201;&#177;&#8201;4.1</p><p>[8.1]</p></td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">6.3&#8201;&#177;&#8201;0.5</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">G<sub>3</sub></td><td align="left" colspan="1" rowspan="1"><p>295.2&#8201;&#177;&#8201;15.14</p><p>[29.4 ]</p></td><td align="left" colspan="1" rowspan="1"><p>10.3&#8201;&#177;&#8201;0.6</p><p>[1.0]</p></td><td align="left" colspan="1" rowspan="1"><p>18.7&#8201;&#177;&#8201;2.9</p><p>[5.5]</p></td><td align="left" colspan="1" rowspan="1"><p>29.3&#8201;&#177;&#8201;5.3</p><p>[11.2]</p></td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">12.5&#8201;&#177;&#8201;0.9</td><td align="left" colspan="1" rowspan="1">12&#8211;14&#160;h fasting</td></tr><tr><td align="left" colspan="1" rowspan="1">G<sub>4</sub></td><td align="left" colspan="1" rowspan="1"><p>285.6&#8201;&#177;&#8201;30.4</p><p>[73.8]</p></td><td align="left" colspan="1" rowspan="1"><p>9.7&#8201;&#177;&#8201;1.2</p><p>[3.0]</p></td><td align="left" colspan="1" rowspan="1"><p>16.6&#8201;&#177;&#8201;3.9</p><p>[7.1]</p></td><td align="left" colspan="1" rowspan="1"><p>15.9&#8201;&#177;&#8201;2.8</p><p>[5.2]</p></td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">13&#8201;&#177;&#8201;7.1</td><td align="left" colspan="1" rowspan="1"><p>12&#8211;14&#160;h fasting; tariquidar (i.p)</p><p>1&#160;h before tracer administration</p></td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>Time between tracer administration and start of scan</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec8"><title>PET Acquisitions</title><p id="Par23">Dynamic brain scans (microPET Focus 220, Siemens Medical Solutions, Malvern, USA) were started simultaneously with tracer injection (G<sub>1</sub>) or immediately after animals were anesthetized following oral tracer administration (G<sub>2</sub>-G<sub>4</sub>) (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). In G<sub>1</sub> and G<sub>2</sub>, a 90&#160;min dynamic scan was followed by an 8&#160;min transmission scan using a <sup>57</sup>Co point source for attenuation and scatter correction. In G<sub>3</sub> and G<sub>4</sub>, a 240&#160;min dynamic scan was performed, followed by a similar transmission scan. In addition, in all groups, a 15&#160;min abdominal PET scan followed by a transmission scan was performed immediately after the brain scan.</p><p id="Par24">To ensure physiological stability, body temperature was maintained using a heating pad and electronic temperature controller for precise regulation. The pad was placed underneath the animal, and the controller monitored rectal temperature via a probe, ensuring it was within a physiological range of 37&#160;&#176;C. Blood oxygenation levels were tracked with pulse oximeter on the paw, and pulse rate was recorded. Throughout all scans, oxygenation, temperature, and pulse rate were continuously monitored to ensure animal well-being and data quality.</p></sec><sec id="Sec9"><title>PET Reconstructions</title><p id="Par25">Brain PET scans of G<sub>1</sub> and G<sub>2</sub> were histogrammed into 24 frames: 6&#8201;&#215;&#8201;10, 4&#8201;&#215;&#8201;30, 2&#8201;&#215;&#8201;60, 1&#8201;&#215;&#8201;120, 1&#8201;&#215;&#8201;180, 4&#8201;&#215;&#8201;300 and 6&#8201;&#215;&#8201;600&#160;s. For G<sub>3</sub> and G<sub>4</sub>, brain PET scans were histogrammed into 20 frames of 720&#160;s. This frame time was suitable as the uptake in these groups was observed to be low and constant throughout the scan duration. Abdomen PET data were histogrammed into a single frame lasting 15&#160;min. Image reconstruction was performed using the Fourier rebinning, high-resolution, two-dimensional ordered-subset expectation maximization (2D OSEM) algorithm with 4 iterations and 16 subsets, after being normalized and corrected for attenuation, scatter, dead time, random coincidences, and radioactivity decay. Reconstructed images were sampled over a grid of 256&#8201;&#215;&#8201;256&#8201;&#215;&#8201;95 voxels, with a zoom of 1.5 and a voxel size of 0.633&#8201;&#215;&#8201;0.633&#8201;&#215;&#8201;0.796 mm<sup>3</sup>.</p></sec><sec id="Sec10"><title><italic toggle="yes">Ex Vivo</italic> Biodistribution</title><p id="Par26">After scanning, animals were terminated by extirpation of the heart under anesthesia. Whole blood, plasma and tissue samples from various brain regions (cortex, midbrain, cerebellum), GI organs (stomach, duodenum, jejunum, ileum, cecum, colon) [<xref ref-type="bibr" rid="CR27">27</xref>], and other organs and tissues (heart, lungs, pancreas, spleen, kidneys, adrenals, liver, muscle, femur) were collected for <italic toggle="yes">ex vivo</italic> analysis. GI contents were removed prior to tissue measurements. These samples were weighed, and radioactivity concentrations were measured using a gamma counter (2480 WIZARD 2, PerkinElmer, Waltham, USA), expressed as kBq/g of tissue. The tissue-to-plasma ratio was calculated to assess the concentration within tissue, relative to plasma, considering the diffusion of the tracer from the GI tract into the bloodstream.</p><sec id="Sec11"><title>Metabolite Analysis</title><p id="Par27">For one animal, from G<sub>4</sub>, the plasma parent fraction was determined following the procedure outlined by Savolainen et al. (2017) [<xref ref-type="bibr" rid="CR19">19</xref>]. Plasma was precipitated by adding two volumes of acetonitrile, followed by centrifugation for 5&#160;min at 6000&#160;rpm. Supernatant samples were then spotted on a thin layer chromatography (TLC, F-254 silica gel plates, Sigma&#8211;Aldrich) plate, which subsequently was eluted with 10% methanol in ethyl acetate. Radioactivity on the plates was detected using phosphor storage imaging using a Cyclone<sup>&#174;</sup> system (PerkinElmer Life and Analytical Science, Waltham, USA). The fractions of intact tracer and radioactive metabolites were calculated by region of interest (ROI) analysis using ImageQuant TL software (PerkinElmer, Waltham, MA, USA).</p></sec></sec><sec id="Sec12"><title>Data Analysis</title><p id="Par28">PET images were co-registered with an [<sup>18</sup>F]MC225-specific brain template for Wistar rats using rigid matching [<xref ref-type="bibr" rid="CR28">28</xref>] and then analyzed using PMOD v4.1 (PMOD Technologies, Zurich, Switzerland). Predefined brain regions were selected as volumes of interest (VOI), and tissue radioactivity (kBq/mL) was determined to generate tissue time-activity curves (TACs).</p><p id="Par29">Standardized uptake value (SUV) images were generated using the following formula:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:SUV=\frac{\text{T}\text{i}\text{s}\text{s}\text{u}\text{e}\:\text{a}\text{c}\text{t}\text{i}\text{v}\text{i}\text{t}\text{y}\:\text{c}\text{o}\text{n}\text{c}\text{e}\text{n}\text{t}\text{r}\text{a}\text{t}\text{i}\text{o}\text{n}\:(\text{k}\text{B}\text{q}/\text{m}\text{L})}{\frac{\text{I}\text{n}\text{j}\text{e}\text{c}\text{t}\text{e}\text{d}\:\text{d}\text{o}\text{s}\text{e}\:\left(\text{M}\text{B}\text{q}\right)}{\text{B}\text{o}\text{d}\text{y}\:\text{w}\text{e}\text{i}\text{g}\text{h}\text{t}\:\left(\text{k}\text{g}\right)}}$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mspace width="0.222222em"/><mml:mi>S</mml:mi><mml:mi>U</mml:mi><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>Tissue</mml:mtext><mml:mspace width="0.222222em"/><mml:mtext>activity</mml:mtext><mml:mspace width="0.222222em"/><mml:mtext>concentration</mml:mtext><mml:mspace width="0.222222em"/><mml:mo stretchy="false">(</mml:mo><mml:mtext>kBq</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>mL</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:mtext>Injected</mml:mtext><mml:mspace width="0.222222em"/><mml:mtext>dose</mml:mtext><mml:mspace width="0.222222em"/><mml:mfenced close=")" open="("><mml:mtext>MBq</mml:mtext></mml:mfenced></mml:mrow><mml:mrow><mml:mtext>Body</mml:mtext><mml:mspace width="0.222222em"/><mml:mtext>weight</mml:mtext><mml:mspace width="0.222222em"/><mml:mfenced close=")" open="("><mml:mtext>kg</mml:mtext></mml:mfenced></mml:mrow></mml:mfrac></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="11307_2024_1975_Article_Equa.gif"/></alternatives></disp-formula></p><sec id="Sec13"><title><italic toggle="yes">In Vitro</italic> Experiment</title><p id="Par30">An <italic toggle="yes">in vitro</italic> experiment was conducted to evaluate the stability of [<sup>18</sup>F]MC225 in the stomach, mimicking low pH and enzymatic conditions as described previously [<xref ref-type="bibr" rid="CR29">29</xref>]. The pH was maintained at 1.7 in both experiments. Enzymatic conditions were assessed using pepsin, a stomach enzyme that serves to digest proteins that are present in ingested food [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par31">The gastric fluid without the enzyme was prepared by dissolving 20&#160;mg of NaCl (sodium chloride) in 70 &#181;L of (12&#160;N)HCl (hydrochloric acid) and 10 mL of water. Simulated gastric fluid was prepared by dissolving 20&#160;mg of NaCl and 32&#160;mg of pepsin from porcine gastric mucosa (&#8805;&#8201;2500 units/mg) in 70 &#181;L of (12&#160;N)HCl and 10 mL of water.</p><p id="Par32">1 mL of each solution was added to a microtube and heated to 37&#160;&#176;C. 50 &#181;L of [<sup>18</sup>F]MC225 was added, and the resulting mixture was stirred at 300&#160;rpm and 37&#160;&#176;C for 2&#160;h. Samples were taken every 30&#160;min and analyzed using TLC according to the same procedure as for the metabolites.</p></sec><sec id="Sec14"><title>Statistics</title><p id="Par33">Descriptive data are presented as mean&#8201;&#177;&#8201;standard deviation (SD) unless otherwise specified.</p></sec></sec><sec id="Sec15" sec-type="results"><title>Results</title><sec id="Sec16"><title>Analysis of PET Data</title><p id="Par34">Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> illustrates both brain and abdominal images for each group in this study. For comparison purposes, attempts were made to establish static brain images with the same time interval between i.v. and oral administration groups. It is important to note that selection of each animal in this figure was based on visual clarity of the image, rather than on radioactivity uptake in the brain. In addition, radioactivity uptake was observed in abdominal organs even after i.v. administration. The supplementary material shows all brain and abdominal PET acquisitions of all animals in three planes: axial, coronal, and sagittal (Supplementary Figs.&#160;<xref rid="MOESM1" ref-type="media">1&#8211;5</xref>).</p><p id="Par35">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Coronal slices through brain images for each group are presented in standardized uptake values (SUV), in g/mL. Static images were acquired from 0 to 90&#160;min for G<sub>1</sub> and G<sub>2</sub>, and from 0 to 96&#160;min for G<sub>3</sub> and G<sub>4</sub>. In addition, 15&#160;min static [<sup>18</sup>F]MC225 PET images of the abdomen are depicted. Abdominal scans are not directly comparable between groups due to differences in acquisition time: for G<sub>1</sub> and G<sub>2</sub>, scans were acquired 98&#160;min after tracer administration, while for G<sub>3</sub> and G<sub>4</sub>, scans were acquired 248&#160;min after tracer administration</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="11307_2024_1975_Fig1_HTML.jpg"/></fig></p><p id="Par36">Visualizing the brain in the oral administration group G<sub>2</sub> was not possible, therefore TACs were not extracted. The esophagus exhibited high radioactivity uptake in the PET image, likely due to the gavage technique, potentially resulting in some spillover effect. However, this does not imply a lack of brain radioactivity uptake; rather, the high tracer concentration in the esophagus obscured the delineation of brain regions. To address these challenges in the subsequent group (G<sub>3</sub>), several measures were implemented. For one animal, a longer needle for oral gavage was introduced, aiming to deliver the tracer closer to the stomach, thus preventing its deposition in the esophagus. In addition, for all animals, fasting was implemented to reduce stomach content, thereby enhancing tracer distribution, especially in the brain. These adjustments facilitated the registration of the PET image template and enabled the subsequent extraction of TACs for each brain region evaluated. In Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, the average TACs of the whole brain for groups G<sub>1</sub>, G<sub>3</sub>, and G<sub>4</sub> are presented.</p><p id="Par37">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>TACs for the whole brain region. G<sub>1</sub>: i.v. injection (90&#160;min of PET acquisition); G<sub>3</sub>: oral administration with 12&#8211;14&#160;h fasting (240&#160;min of PET acquisition); G<sub>4</sub>: oral administration with 12&#8211;14&#160;h fasting and tariquidar i.p. injection (240&#160;min of PET acquisition)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="11307_2024_1975_Fig2_HTML.jpg"/></fig></p><p id="Par38">Low but constant radioactivity uptake in the brain was observed in G<sub>3</sub> and G<sub>4</sub>. Administration of tariquidar, a P-gp inhibitor, did not result in higher SUV values in the brain (G<sub>4</sub>vs. G<sub>3</sub>).</p></sec><sec id="Sec17"><title><italic toggle="yes">Ex Vivo</italic> Biodistribution</title><p id="Par39">The time between tracer injection and counting of radioactivity was recorded for each group. For G<sub>1</sub>, the time was 174&#8201;&#177;&#8201;18&#160;min; for G<sub>2</sub>, it was 178&#8201;&#177;&#8201;4&#160;min, and for G<sub>3</sub> and G<sub>4</sub>, the times were 333&#8201;&#177;&#8201;10 and 333&#8201;&#177;&#8201;14&#160;min, respectively.</p><p id="Par40"> Overall, oral administration resulted in lower brain tracer concentrations compared with i.v. injection, by approximately 51% for the cortex and 45% for the midbrain and cerebellum. Figures&#160;<xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref> and <xref rid="Fig5" ref-type="fig">5</xref> present <italic toggle="yes">ex vivo</italic> results for brain and whole blood (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>), the GI tract (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>), and other organs and tissues (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>), adjusting for changes in delivery (plasma concentration). The supplementary material shows the results in terms of kBq/g and tissue-to-plasma ratios (Tables&#160;<xref rid="Tab1" ref-type="table">1</xref> and 2).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><italic toggle="yes">Ex vivo </italic>results for brain and whole blood (mean&#8201;&#177;&#8201;SD). Results are expressed in terms of tissue-to-plasma ratio. The animal in G<sub>3</sub> plotted in black received the oral gavage with a longer needle. For G<sub>1</sub> the time between tracer administration and biodistribution was 174&#8201;&#177;&#8201;18&#160;min, for G<sub>2</sub> it was 178&#8201;&#177;&#8201;4&#160;min, and for G<sub>3</sub> and G<sub>4</sub> the time was 333&#8201;&#177;&#8201;10&#160;min and 333&#8201;&#177;&#8201;14&#160;min, respectively</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="11307_2024_1975_Fig3_HTML.jpg"/></fig></p><p id="Par41">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><italic toggle="yes">Ex vivo</italic> results for GI tract (mean&#8201;&#177;&#8201;SD). Results are expressed in terms of tissue-to-plasma ratio. The animal in G<sub>3</sub> plotted in black received the oral gavage with a longer needle. For G<sub>1</sub> the time between tracer administration and biodistribution was 174&#8201;&#177;&#8201;18&#160;min, for G<sub>2</sub> it was 178&#8201;&#177;&#8201;4&#160;min, and for G<sub>3</sub> and G<sub>4</sub> the time was 333&#8201;&#177;&#8201;10&#160;min and 333&#8201;&#177;&#8201;14&#160;min, respectively</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="11307_2024_1975_Fig4_HTML.jpg"/></fig></p><p id="Par42">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p><italic toggle="yes">Ex vivo</italic> results for other organs and tissues (mean&#8201;&#177;&#8201;SD). Results are expressed in terms of tissue-to-plasma ratio. The animal in G<sub>3</sub> plotted in black received the oral gavage with a longer needle. For G<sub>1</sub> the time between tracer administration and biodistribution was 174&#8201;&#177;&#8201;18&#160;min, for G<sub>2</sub> it was 178&#8201;&#177;&#8201;4&#160;min, and for G<sub>3</sub> and G<sub>4</sub> the time was 333&#8201;&#177;&#8201;10 and 333&#8201;&#177;&#8201;14&#160;min, respectively</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="11307_2024_1975_Fig5_HTML.jpg"/></fig></p><p id="Par43">In the tariquidar-treated group (G<sub>4</sub>), there was an increase of 4% in the cortex, 13% in midbrain, and 6% in cerebellum compared with G<sub>3</sub>. It should be noted, however, that despite the increase in tissue-to-plasma ratios in G<sub>4</sub> compared with G<sub>3</sub>, actual brain tracer concentrations decreased, as plasma levels were much lower in G<sub>4</sub> than in G<sub>3</sub>. For the other organs and tissues evaluated, there were no obvious differences between groups G<sub>3</sub> and G<sub>4</sub>.</p></sec><sec id="Sec18"><title>Metabolite Analysis</title><p id="Par44">Results for the G<sub>4</sub> prompted an investigation into plasma metabolites, aiming to elucidate the reasons behind the absence of increased brain radioactivity uptake observed after the use of tariquidar. This revealed that only 4.1% of the total radioactivity in plasma was related to the parent tracer, with a dominant presence of labelled polar metabolites (91%). Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">6</xref> shows TLC plates with the respective analyses.</p></sec><sec id="Sec19"><title><italic toggle="yes">In Vitro</italic> Experiment</title><p id="Par45">[<sup>18</sup>F]MC225 showed stability under simulated gastric conditions for up to 2&#160;h, with no significant decomposition observed in the acidic environment. The amount of intact tracer at <italic toggle="yes">t</italic>&#8201;=&#8201;0&#160;min corresponded with the radiochemical purity, which was higher than 95%. In the gastric fluid without pepsin, 86% of the tracer remained intact after 30&#160;min, with no significant change (remaining 88%) after 120&#160;min. In the solution containing pepsin, the tracer stability was slightly higher, with 92% intact after 30&#160;min, and a similar pattern of stability observed over time, ending with 92% intact after 120&#160;min.</p></sec></sec><sec id="Sec20" sec-type="discussion"><title>Discussion</title><p id="Par46">This preclinical PET imaging study assessed the feasibility of orally administering the P-gp substrate [<sup>18</sup>F]MC225 and quantifying it for both the brain and GI tract. P-gp, as a crucial regulator of drug concentrations in the blood, brain, and other tissues, plays a pivotal role in drug transport across the basolateral membrane. Understanding P-gp function in the intestine is particularly relevant for understanding variations in drug treatment, especially in pharmacoresistant patients [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par47">As anticipated, oral administration yielded lower tracer concentrations in the brain compared with i.v. administration (G<sub>1</sub>vs. G<sub>2</sub>) [<xref ref-type="bibr" rid="CR8">8</xref>]. Methodological changes, such as varying the amount of administered activity, using longer needles, animal fasting and modifying the acquisition duration, were explored to optimize tracer quantification. For the brain, these modifications resulted in higher uptake and better visualization (G<sub>3</sub>vs. G<sub>2</sub>), and this was confirmed by the <italic toggle="yes">ex vivo</italic> results, even with a difference of 2.5&#160;h (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par48">Analysis of the GI tract images was not conducted due to challenges of distinguishing the tracer signal within the GI lumen from that related to transport within the bloodstream. Notably, the change of needle size had a significant impact on the tracer distribution. Deposition of the tracer in the esophagus is related to the concept of oral administration by gavage. With this technique, the tracer is delivered near the gastro-esophageal sphincter rather than directly into the stomach, as it is done with gastrostomy. Although the administration of the tracer was slow, esophageal reflux occurred [<xref ref-type="bibr" rid="CR31">31</xref>] and the lipophilic and sticky nature of [<sup>18</sup>F]MC225 may have contributed to its adherence to the tissue. While switching to a longer needle may not yield benefits for non-radioactive compounds and could increase the risk of perforation, it proved advantageous in imaging studies involving radioactive compounds.</p><p id="Par49">Contrary to expectations, the group receiving the P-gp inhibitor tariquidar (G<sub>4</sub>) did not exhibit a higher brain concentration than those without (G<sub>3</sub>). Higher tracer concentration was expected as inhibiting the P-gp transporter typically leads to increased tracer diffusion into cells, particularly in the brain and plasma, as demonstrated in previous studies [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. This unexpected finding suggests that the observed signal is dominated by non-specific uptake. Indeed, analysis of metabolites in plasma showed a high fraction of small labeled polar metabolites that reach the whole blood compartment via diffusion. Five hours after administration, only 4.1% of the total radioactivity in plasma represented intact tracer, supporting the hypothesis that the signal in the brain was dominated by radiolabeled metabolites rather than parent [<sup>18</sup>F]MC225. However, it is not possible to draw definitive conclusions from this observation, as it was derived from one blood sample obtained from one animal five hours after tracer administration. Interestingly, radioactivity concentration in the bone (femur) was attributed to defluorination during [<sup>18</sup>F]MC225 metabolism as previously described [<xref ref-type="bibr" rid="CR19">19</xref>]. For the oral administration route, the tissue-to-plasma ratio of bone was lower compared with the i.v. route, indicating that metabolism of the tracer differed between these two administration methods.</p><p id="Par50"><italic toggle="yes">In vitro</italic> stability studies revealed that [<sup>18</sup>F]MC225 is stable under simulated gastric conditions, suggesting that the challenges associated with oral administration of [<sup>18</sup>F]MC225 are not due to instability in the stomach. This stability under gastric conditions indicates that the breakdown and formation of metabolites likely occur when the tracer reaches the intestine. One possible explanation is that enterocytes, which express P-gp and enzymes such as CYP3A4, play a significant role in drug metabolism within the GI tract [<xref ref-type="bibr" rid="CR32">32</xref>]. P-gp and CYP3A4 are co-localized in enterocytes, share common substrates, and are co-inducible in response to some xenobiotics [<xref ref-type="bibr" rid="CR32">32</xref>]. It is likely that [<sup>18</sup>F]MC225 enters the enterocyte via diffusion and is promptly metabolized before being expelled from the cell via the P-gp efflux pump. This metabolic process of uptake by diffusion and efflux by active transport occurs throughout the small intestine, which could partially explain the oscillation observed in the tissue TAC of G<sub>3</sub>. This effect is not seen when the P-gp inhibitor tariquidar is administered in conjunction with the radioligand in G<sub>4</sub> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Future studies are warranted to comprehensively investigate the uptake and metabolism of [<sup>18</sup>F]MC225 in the intestine to elucidate these dynamics further.</p><p id="Par51">While the present results do not support the feasibility of oral administration of [<sup>18</sup>F]MC225, they underscore the significant challenges associated with this method, particularly concerning metabolizing enzymes in the GIT. A repeated G<sub>2</sub> study could potentially improve the groups&#8217; comparisons regarding the feasibility of administering tracers via this route. However, the principles of the 3Rs (Replacement, Reduction and Refinement) in animal research did not justify additional experiments. Although the PET images from this study were not of satisfactory quality because of high radioactivity concentration in the esophagus, conclusions were drawn from the corresponding <italic toggle="yes">ex vivo</italic> biodistribution results and the comparison between G<sub>3</sub> and G<sub>4</sub>. Continuing the study would subject the animals to unnecessary procedures and discomfort without yielding directly meaningful or beneficial data.</p><p id="Par52">Prior to further PET scans, rigorous <italic toggle="yes">in vitro</italic> studies are essential to assess tracer stability and metabolism in both the stomach and intestine. These studies are crucial for advancing the feasibility and reliability of oral tracer administration. Moreover, utilizing the already available 3D organoids system of small intestine could provide valuable insights into the impact of P-gp function on the absorption and metabolization of [<sup>18</sup>F]MC225 within the intestine, particularly concerning the effects of P-gp dysfunction [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p></sec><sec id="Sec21" sec-type="conclusion"><title>Conclusions</title><p id="Par53">Oral administration of [<sup>18</sup>F]MC225 resulted in an unexpected high level of radiolabeled metabolites together with the lack of a response to P-gp inhibition, warrant furthering investigation into tracer metabolism. These findings underscore the importance of a better understanding of GI tract physiology and its impact on tracer absorption and breakdown to refine oral administration protocols and optimize tracer delivery to target tissues.</p></sec><sec id="Sec22" sec-type="supplementary-material"><title>Electronic Supplementary Material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11307_2024_1975_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contributions</title><p>Giordana Salvi de Souza: Conceptualization, methodology, investigation, formal analysis, writing &#8211; original draft, review &amp; editing; Cristiane Furini: Conceptualization, methodology, supervision, writing &#8211; review &amp; editing; J&#252;rgen Sijbesma: Investigation; Maria Kominia: Investigation; Janine Doorduin: Conceptualization, methodology; Bruno Lima Giacobbo: writing &#8211; review &amp; editing Adriaan Lammertsma: Conceptualization, writing &#8211; review &amp; editing; Charalampos Tsoumpas: Conceptualization, supervision, writing &#8211; review &amp; editing; Gert Luurtsema: Conceptualization, methodology, project administration, supervision, writing &#8211; review &amp; editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Abel Tasman Talent Program (ATTP) of the Graduate School of Medical Sciences of the University of Groningen, the Netherlands.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>All research data are available from the corresponding author upon request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethical Approval</title><p id="Par54">This study followed all applicable institutional and/or national guidelines for the care and use of animals.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par55">The authors declare no conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapoor</surname><given-names>K</given-names></name><name name-style="western"><surname>Pant</surname><given-names>S</given-names></name><name name-style="western"><surname>Tajkhorshid</surname><given-names>E</given-names></name></person-group><article-title>Active participation of membrane lipids in inhibition of multidrug transporter P-glycoprotein</article-title><source>Chem Sci J</source><year>2021</year><volume>12</volume><fpage>6293</fpage><lpage>6306</lpage><pub-id pub-id-type="doi">10.1039/D0SC06288J</pub-id><pub-id pub-id-type="pmcid">PMC8115088</pub-id><pub-id pub-id-type="pmid">34084427</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Kapoor K, Pant S, Tajkhorshid E (2021) Active participation of membrane lipids in inhibition of multidrug transporter P-glycoprotein. Chem Sci J 12:6293&#8211;6306. 10.1039/D0SC06288J<pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0sc06288j</pub-id><pub-id pub-id-type="pmcid">PMC8115088</pub-id><pub-id pub-id-type="pmid">34084427</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name></person-group><article-title>P-Glycoprotein and bioavailability-implication of polymorphism</article-title><source>Clin Chem Lab Med</source><year>2000</year><volume>38</volume><fpage>877</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1515/CCLM.2000.127</pub-id><pub-id pub-id-type="pmid">11097343</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Liu Y, Hu M (2000) P-Glycoprotein and bioavailability-implication of polymorphism. Clin Chem Lab Med 38:877&#8211;881. 10.1515/CCLM.2000.127<pub-id pub-id-type="pmid">11097343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/CCLM.2000.127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed Juvale</surname><given-names>II</given-names></name><name name-style="western"><surname>Abdul Hamid</surname><given-names>AA</given-names></name><name name-style="western"><surname>Abd Halim</surname><given-names>KB</given-names></name><name name-style="western"><surname>Che Has</surname><given-names>AT</given-names></name></person-group><article-title>P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease</article-title><source>Heliyon</source><year>2022</year><volume>8</volume><fpage>e09777</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e09777</pub-id><pub-id pub-id-type="pmid">35789865</pub-id><pub-id pub-id-type="pmcid">PMC9249865</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ahmed Juvale II, Abdul Hamid AA, Abd Halim KB, Che Has AT (2022) P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease. Heliyon 8:e09777. 10.1016/j.heliyon.2022.e09777<pub-id pub-id-type="pmid">35789865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2022.e09777</pub-id><pub-id pub-id-type="pmcid">PMC9249865</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfarouk</surname><given-names>KO</given-names></name><name name-style="western"><surname>Stock</surname><given-names>C-M</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>S</given-names></name><etal/></person-group><article-title>Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp</article-title><source>Cancer Cell Int</source><year>2015</year><volume>15</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/s12935-015-0221-1</pub-id><pub-id pub-id-type="pmid">26180516</pub-id><pub-id pub-id-type="pmcid">PMC4502609</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Alfarouk KO, Stock C-M, Taylor S et al (2015) Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int 15:71. 10.1186/s12935-015-0221-1<pub-id pub-id-type="pmid">26180516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-015-0221-1</pub-id><pub-id pub-id-type="pmcid">PMC4502609</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murakami</surname><given-names>T</given-names></name><name name-style="western"><surname>Bodor</surname><given-names>E</given-names></name><name name-style="western"><surname>Bodor</surname><given-names>N</given-names></name></person-group><article-title>Modulation of expression/function of intestinal P-glycoprotein under disease states</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2020</year><volume>16</volume><fpage>59</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1080/17425255.2020.1701653</pub-id><pub-id pub-id-type="pmid">31821048</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Murakami T, Bodor E, Bodor N (2020) Modulation of expression/function of intestinal P-glycoprotein under disease states. Expert Opin Drug Metab Toxicol 16:59&#8211;78. 10.1080/17425255.2020.1701653<pub-id pub-id-type="pmid">31821048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425255.2020.1701653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoosain</surname><given-names>FG</given-names></name><name name-style="western"><surname>Choonara</surname><given-names>YE</given-names></name><name name-style="western"><surname>Tomar</surname><given-names>LK</given-names></name><etal/></person-group><article-title>Bypassing P-Glycoprotein drug efflux mechanisms: possible applications in Pharmacoresistant Schizophrenia Therapy</article-title><source>Biomed Res Int</source><year>2015</year><volume>2015</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1155/2015/484963</pub-id><pub-id pub-id-type="pmcid">PMC4600488</pub-id><pub-id pub-id-type="pmid">26491671</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Hoosain FG, Choonara YE, Tomar LK et al (2015) Bypassing P-Glycoprotein drug efflux mechanisms: possible applications in Pharmacoresistant Schizophrenia Therapy. Biomed Res Int 2015:1&#8211;21. 10.1155/2015/484963<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/484963</pub-id><pub-id pub-id-type="pmcid">PMC4600488</pub-id><pub-id pub-id-type="pmid">26491671</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartels</surname><given-names>L</given-names></name><name name-style="western"><surname>de Klerk</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kortekaas</surname><given-names>O</given-names></name><etal/></person-group><article-title>11 C-verapamil to assess P-gp function in human brain during aging,Depression and neurodegenerative disease</article-title><source>Curr Top Med Chem</source><year>2010</year><volume>10</volume><fpage>1775</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.2174/156802610792928059</pub-id><pub-id pub-id-type="pmid">20645917</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bartels L, de Klerk AL, Kortekaas O et al (2010) 11 C-verapamil to assess P-gp function in human brain during aging,Depression and neurodegenerative disease. Curr Top Med Chem 10:1775&#8211;1784. 10.2174/156802610792928059<pub-id pub-id-type="pmid">20645917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/156802610792928059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvi de Souza</surname><given-names>G</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>DBA</given-names></name><name name-style="western"><surname>Mossel</surname><given-names>P</given-names></name><etal/></person-group><article-title>Oral administration of PET tracers: current status</article-title><source>J Control Release</source><year>2023</year><volume>357</volume><fpage>591</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.04.008</pub-id><pub-id pub-id-type="pmid">37031742</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Salvi de Souza G, Mantovani DBA, Mossel P et al (2023) Oral administration of PET tracers: current status. J Control Release 357:591&#8211;605. 10.1016/j.jconrel.2023.04.008<pub-id pub-id-type="pmid">37031742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.04.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kataoka</surname><given-names>M</given-names></name><name name-style="western"><surname>Takashima</surname><given-names>T</given-names></name><name name-style="western"><surname>Shingaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Dynamic analysis of GI absorption and hepatic distribution processes of Telmisartan in rats using Positron Emission Tomography</article-title><source>Pharm Res</source><year>2012</year><volume>29</volume><fpage>2419</fpage><lpage>2431</lpage><pub-id pub-id-type="doi">10.1007/s11095-012-0768-7</pub-id><pub-id pub-id-type="pmid">22618800</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Kataoka M, Takashima T, Shingaki T et al (2012) Dynamic analysis of GI absorption and hepatic distribution processes of Telmisartan in rats using Positron Emission Tomography. Pharm Res 29:2419&#8211;2431. 10.1007/s11095-012-0768-7<pub-id pub-id-type="pmid">22618800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-012-0768-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>K</given-names></name><etal/></person-group><article-title>Is enteral administration of fluorine-18-fluorodeoxyglucose (F-18 FDG) a palatable alternative to IV injection?</article-title><source>Nucl Med Biol</source><year>2002</year><volume>29</volume><fpage>363</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/S0969-8051(01)00312-2</pub-id><pub-id pub-id-type="pmid">11929708</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Higashi T, Fisher SJ, Nakada K et al (2002) Is enteral administration of fluorine-18-fluorodeoxyglucose (F-18 FDG) a palatable alternative to IV injection? Nucl Med Biol 29:363&#8211;373. 10.1016/S0969-8051(01)00312-2<pub-id pub-id-type="pmid">11929708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0969-8051(01)00312-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shingaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakaoka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Exploration of antiemetics for osteoporosis therapy-induced nausea and vomiting using PET molecular imaging analysis to gastrointestinal pharmacokinetics</article-title><source>Pharm Res</source><year>2016</year><volume>33</volume><fpage>1235</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1007/s11095-016-1868-6</pub-id><pub-id pub-id-type="pmid">26869173</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Shingaki T, Katayama Y, Nakaoka T et al (2016) Exploration of Antiemetics for osteoporosis Therapy-Induced nausea and Vomiting Using PET Molecular Imaging Analysis to gastrointestinal pharmacokinetics. Pharm Res 33:1235&#8211;1248. 10.1007/s11095-016-1868-6<pub-id pub-id-type="pmid">26869173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-016-1868-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mossel</surname><given-names>P</given-names></name><name name-style="western"><surname>Garcia Varela</surname><given-names>L</given-names></name><name name-style="western"><surname>Arif</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Evaluation of P-glycoprotein function at the blood&#8211;brain barrier using [18F]MC225-PET</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2021</year><volume>48</volume><fpage>4105</fpage><pub-id pub-id-type="doi">10.1007/s00259-021-05419-8</pub-id><pub-id pub-id-type="pmid">34089347</pub-id><pub-id pub-id-type="pmcid">PMC8484189</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Mossel P, Garcia Varela L, Arif WM et al (2021) Evaluation of P-glycoprotein function at the blood&#8211;brain barrier using [18F]MC225-PET. Eur J Nucl Med Mol Imaging 48:4105. 10.1007/s00259-021-05419-8<pub-id pub-id-type="pmid">34089347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-021-05419-8</pub-id><pub-id pub-id-type="pmcid">PMC8484189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toyohara</surname><given-names>J</given-names></name><name name-style="western"><surname>Sakata</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood&#8211;brain barrier</article-title><source>Ann Nucl Med</source><year>2021</year><volume>35</volume><fpage>1240</fpage><pub-id pub-id-type="doi">10.1007/s12149-021-01666-9</pub-id><pub-id pub-id-type="pmid">34368924</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Toyohara J, Sakata M, Ishibashi K et al (2021) First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood&#8211;brain barrier. Ann Nucl Med 35:1240. 10.1007/s12149-021-01666-9<pub-id pub-id-type="pmid">34368924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12149-021-01666-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mossel</surname><given-names>P</given-names></name><name name-style="western"><surname>Arif</surname><given-names>WM</given-names></name><name name-style="western"><surname>De Souza</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Quantification of P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2023</year><pub-id pub-id-type="doi">10.1007/s00259-023-06363-5</pub-id><pub-id pub-id-type="pmid">37552369</pub-id><pub-id pub-id-type="pmcid">PMC10611838</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Mossel P, Arif WM, De Souza GS et al (2023) Quantification of P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET. Eur J Nucl Med Mol Imaging. 10.1007/s00259-023-06363-5<pub-id pub-id-type="pmid">37552369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-023-06363-5</pub-id><pub-id pub-id-type="pmcid">PMC10611838</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Varela</surname><given-names>L</given-names></name><name name-style="western"><surname>Mossel</surname><given-names>P</given-names></name><name name-style="western"><surname>Aguiar</surname><given-names>P</given-names></name><etal/></person-group><article-title>Dose-response assessment of cerebral P-glycoprotein inhibition in vivo with [18F]MC225 and PET</article-title><source>J Control Release</source><year>2022</year><volume>347</volume><fpage>500</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.05.026</pub-id><pub-id pub-id-type="pmid">35588934</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Garcia-Varela L, Mossel P, Aguiar P et al (2022) Dose-response assessment of cerebral P-glycoprotein inhibition <italic toggle="yes">in vivo</italic> with [18F]MC225 and PET. J Control Release 347:500&#8211;507. 10.1016/j.jconrel.2022.05.026<pub-id pub-id-type="pmid">35588934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.05.026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shugarts</surname><given-names>S</given-names></name><name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></name></person-group><article-title>The role of transporters in the pharmacokinetics of orally administered drugs</article-title><source>Pharm Res</source><year>2009</year><volume>26</volume><fpage>2039</fpage><lpage>2054</lpage><pub-id pub-id-type="doi">10.1007/s11095-009-9924-0</pub-id><pub-id pub-id-type="pmid">19568696</pub-id><pub-id pub-id-type="pmcid">PMC2719753</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Shugarts S, Benet LZ (2009) The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26:2039&#8211;2054. 10.1007/s11095-009-9924-0<pub-id pub-id-type="pmid">19568696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-009-9924-0</pub-id><pub-id pub-id-type="pmcid">PMC2719753</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavhane</surname><given-names>YN</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>AV</given-names></name></person-group><article-title>Loss of orally administered drugs in GI tract</article-title><source>Saudi Pharm J</source><year>2012</year><volume>20</volume><fpage>331</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2012.03.005</pub-id><pub-id pub-id-type="pmid">23960808</pub-id><pub-id pub-id-type="pmcid">PMC3744959</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Gavhane YN, Yadav AV (2012) Loss of orally administered drugs in GI tract. Saudi Pharm J 20:331&#8211;344. 10.1016/j.jsps.2012.03.005<pub-id pub-id-type="pmid">23960808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsps.2012.03.005</pub-id><pub-id pub-id-type="pmcid">PMC3744959</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savolainen</surname><given-names>H</given-names></name><name name-style="western"><surname>Cantore</surname><given-names>M</given-names></name><name name-style="western"><surname>Colabufo</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Synthesis and preclinical evaluation of three Novel Fluorine-18 labeled Radiopharmaceuticals for P-Glycoprotein PET imaging at the blood-brain barrier</article-title><source>Mol Pharm</source><year>2015</year><volume>12</volume><fpage>2265</fpage><pub-id pub-id-type="doi">10.1021/mp5008103</pub-id><pub-id pub-id-type="pmid">26043236</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Savolainen H, Cantore M, Colabufo NA et al (2015) Synthesis and preclinical evaluation of three Novel Fluorine-18 labeled Radiopharmaceuticals for P-Glycoprotein PET imaging at the blood-brain barrier. Mol Pharm 12:2265. 10.1021/mp5008103<pub-id pub-id-type="pmid">26043236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/mp5008103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savolainen</surname><given-names>H</given-names></name><name name-style="western"><surname>Windhorst</surname><given-names>AD</given-names></name><name name-style="western"><surname>Elsinga</surname><given-names>PH</given-names></name><etal/></person-group><article-title>Evaluation of [<sup>18</sup> F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood&#8211;brain barrier in rats: kinetics, metabolism, and selectivity</article-title><source>J Cereb Blood Flow Metab</source><year>2017</year><volume>37</volume><fpage>1286</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1177/0271678X16654493</pub-id><pub-id pub-id-type="pmid">27354093</pub-id><pub-id pub-id-type="pmcid">PMC5453451</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Savolainen H, Windhorst AD, Elsinga PH et al (2017) Evaluation of [<sup>18</sup> F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood&#8211;brain barrier in rats: kinetics, metabolism, and selectivity. J Cereb Blood Flow Metab 37:1286&#8211;1298. 10.1177/0271678X16654493<pub-id pub-id-type="pmid">27354093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0271678X16654493</pub-id><pub-id pub-id-type="pmcid">PMC5453451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madla</surname><given-names>CM</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gavins</surname><given-names>FKH</given-names></name><etal/></person-group><article-title>Sex differences in intestinal P-Glycoprotein expression in Wistar versus Sprague Dawley rats</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><fpage>1030</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14051030</pub-id><pub-id pub-id-type="pmid">35631615</pub-id><pub-id pub-id-type="pmcid">PMC9143158</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Madla CM, Qin Y, Gavins FKH et al (2022) Sex differences in intestinal P-Glycoprotein expression in Wistar versus Sprague Dawley rats. Pharmaceutics 14:1030. 10.3390/pharmaceutics14051030<pub-id pub-id-type="pmid">35631615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics14051030</pub-id><pub-id pub-id-type="pmcid">PMC9143158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Schreiber D, Markus K, Kerstin L et al (2014) The mesenterially perfused rat small intestine: a versatile approach for pharmacological testings. Annals Anat 196. 10.1016/j.aanat.2014.02.008<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.aanat.2014.02.008</pub-id><pub-id pub-id-type="pmid">24690290</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Albrecht M, Henke J, Tacke S et al (2014) Influence of repeated anaesthesia on physiological parameters in male Wistar rats: a telemetric study about isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl. BMC Vet Res 10:310. 10.1186/s12917-014-0310-8<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12917-014-0310-8</pub-id><pub-id pub-id-type="pmcid">PMC4301083</pub-id><pub-id pub-id-type="pmid">25551200</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gatley</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Thanos</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Brain kinetics of methylphenidate (ritalin) enantiomers after oral administration</article-title><source>Synapse</source><year>2004</year><volume>53</volume><fpage>168</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1002/syn.20046</pub-id><pub-id pub-id-type="pmid">15236349</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ding Y, Gatley SJ, Thanos PK et al (2004) Brain kinetics of methylphenidate (ritalin) enantiomers after oral administration. Synapse 53:168&#8211;175. 10.1002/syn.20046<pub-id pub-id-type="pmid">15236349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/syn.20046</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamashita</surname><given-names>S</given-names></name><name name-style="western"><surname>Takashima</surname><given-names>T</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>M</given-names></name><etal/></person-group><article-title>PET imaging of the gastrointestinal absorption of orally administered drugs in conscious and anesthetized rats</article-title><source>J Nucl Med</source><year>2011</year><volume>52</volume><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.2967/jnumed.110.081539</pub-id><pub-id pub-id-type="pmid">21233189</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Yamashita S, Takashima T, Kataoka M et al (2011) PET imaging of the gastrointestinal absorption of orally administered drugs in conscious and anesthetized rats. J Nucl Med 52:249&#8211;256. 10.2967/jnumed.110.081539<pub-id pub-id-type="pmid">21233189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.110.081539</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eichenbaum</surname><given-names>G</given-names></name><name name-style="western"><surname>Damsch</surname><given-names>S</given-names></name><name name-style="western"><surname>Looszova</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impact of gavage dosing procedure and gastric content on adverse respiratory effects and mortality in rat toxicity studies</article-title><source>J Appl Toxicol</source><year>2011</year><volume>31</volume><fpage>342</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1002/jat.1592</pub-id><pub-id pub-id-type="pmid">21089156</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Eichenbaum G, Damsch S, Looszova A et al (2011) Impact of gavage dosing procedure and gastric content on adverse respiratory effects and mortality in rat toxicity studies. J Appl Toxicol 31:342&#8211;354. 10.1002/jat.1592<pub-id pub-id-type="pmid">21089156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jat.1592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matzneller</surname><given-names>P</given-names></name><name name-style="western"><surname>Kussmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Eberl</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pharmacokinetics of the P-gp inhibitor tariquidar in rats after intravenous, oral, and Intraperitoneal Administration</article-title><source>Eur J Drug Metab Pharmacokinet</source><year>2018</year><volume>43</volume><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1007/s13318-018-0474-x</pub-id><pub-id pub-id-type="pmid">29616423</pub-id><pub-id pub-id-type="pmcid">PMC6133083</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Matzneller P, Kussmann M, Eberl S et al (2018) Pharmacokinetics of the P-gp inhibitor tariquidar in rats after intravenous, oral, and Intraperitoneal Administration. Eur J Drug Metab Pharmacokinet 43:599&#8211;606. 10.1007/s13318-018-0474-x<pub-id pub-id-type="pmid">29616423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13318-018-0474-x</pub-id><pub-id pub-id-type="pmcid">PMC6133083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeSesso</surname><given-names>JM</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>CF</given-names></name></person-group><article-title>Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats</article-title><source>Food Chem Toxicol</source><year>2001</year><volume>39</volume><fpage>209</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/S0278-6915(00)00136-8</pub-id><pub-id pub-id-type="pmid">11278053</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">DeSesso JM, Jacobson CF (2001) Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 39:209&#8211;228. 10.1016/S0278-6915(00)00136-8<pub-id pub-id-type="pmid">11278053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0278-6915(00)00136-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Varela</surname><given-names>L</given-names></name><name name-style="western"><surname>V&#225;llez Garc&#237;a</surname><given-names>D</given-names></name><name name-style="western"><surname>Rodr&#237;guez-P&#233;rez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Test&#8211;retest repeatability of [ <sup>18</sup> F]MC225-PET in rodents: a Tracer for imaging of P-gp function</article-title><source>ACS Chem Neurosci</source><year>2020</year><volume>11</volume><fpage>648</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.9b00682</pub-id><pub-id pub-id-type="pmid">31961646</pub-id><pub-id pub-id-type="pmcid">PMC7034080</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Garc&#237;a-Varela L, V&#225;llez Garc&#237;a D, Rodr&#237;guez-P&#233;rez M et al (2020) Test&#8211;retest repeatability of [ <sup>18</sup> F]MC225-PET in rodents: a Tracer for imaging of P-gp function. ACS Chem Neurosci 11:648&#8211;658. 10.1021/acschemneuro.9b00682<pub-id pub-id-type="pmid">31961646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.9b00682</pub-id><pub-id pub-id-type="pmcid">PMC7034080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Pharmacopeia</surname><given-names>US</given-names></name></person-group><source>The United States pharmacopeia: USP 29; the National formulary: NF 24</source><year>2006</year><publisher-loc>Rockville,Maryland</publisher-loc><publisher-name>US Pharmacopeial Convention</publisher-name></element-citation><mixed-citation id="mc-CR29" publication-type="book">Pharmacopeia US (2006) The United States pharmacopeia: USP 29; the National formulary: NF 24. US Pharmacopeial Convention, Rockville,Maryland</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Rowbotham DJ, Kimpson PM, Thompson HM (2006) Gut motility and secretions. In: Hemmings HC, Hopkins PM (eds) Foundations of anesthesia, 2nd edn. Elsevier, pp 739&#8211;751.&#160;10.1016/B978-0-323-03707-5.50067-X. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.sciencedirect.com/science/article/pii/B978032303707550067X">https://www.sciencedirect.com/science/article/pii/B978032303707550067X</ext-link></mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damsch</surname><given-names>S</given-names></name><name name-style="western"><surname>Eichenbaum</surname><given-names>G</given-names></name><name name-style="western"><surname>Tonelli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Gavage-related reflux in rats</article-title><source>Toxicol Pathol</source><year>2011</year><volume>39</volume><fpage>348</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1177/0192623310388431</pub-id><pub-id pub-id-type="pmid">21422261</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Damsch S, Eichenbaum G, Tonelli A et al (2011) Gavage-related reflux in rats. Toxicol Pathol 39:348&#8211;360. 10.1177/0192623310388431<pub-id pub-id-type="pmid">21422261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0192623310388431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watkins</surname><given-names>P</given-names></name></person-group><article-title>The barrier function of CYP3A4 and P-glycoprotein in the small bowel</article-title><source>Adv Drug Deliv Rev</source><year>1997</year><volume>27</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(97)00041-0</pub-id><pub-id pub-id-type="pmid">10837556</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Watkins P (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161&#8211;170. 10.1016/S0169-409X(97)00041-0<pub-id pub-id-type="pmid">10837556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-409x(97)00041-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>S</given-names></name><name name-style="western"><surname>Miwa</surname><given-names>H</given-names></name><name name-style="western"><surname>Kawachi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Generation of intestinal organoids derived from human pluripotent stem cells for drug testing</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>5989</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-63151-z</pub-id><pub-id pub-id-type="pmid">32249832</pub-id><pub-id pub-id-type="pmcid">PMC7136241</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Yoshida S, Miwa H, Kawachi T et al (2020) Generation of intestinal organoids derived from human pluripotent stem cells for drug testing. Sci Rep 10:5989. 10.1038/s41598-020-63151-z<pub-id pub-id-type="pmid">32249832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-63151-z</pub-id><pub-id pub-id-type="pmcid">PMC7136241</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><etal/></person-group><article-title>A novel model of P-Glycoprotein inhibitor screening using human small intestinal organoids</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2017</year><volume>120</volume><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1111/bcpt.12680</pub-id><pub-id pub-id-type="pmid">27657920</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Zhao J, Zeng Z, Sun J et al (2017) A novel model of P-Glycoprotein inhibitor screening using human small intestinal organoids. Basic Clin Pharmacol Toxicol 120:250&#8211;255. 10.1111/bcpt.12680<pub-id pub-id-type="pmid">27657920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcpt.12680</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>